Company / Free Cash Flow
Tarsus Pharmaceuticals, Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$22.3M
FY2025
5-year range
-$119.0M / $3.2M
FY2021-FY2025
Trend
+73.6%
vs FY2024
Sector context
#72 of 194
Health Care
What the data says
At -$22M, Tarsus Pharmaceuticals, Inc.'s free cash flow ranks #72 of 194 in the Health Care sector. Improved from -$119M to -$22M over the past 2 years.
Based on SEC 10-K filings.
-$22M in FY2025.
Improved from -$119M to -$22M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#72 of 194 in Health CareTop 37% of 194This company -$22.3M Sector average $470.6M
▼
-104.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 73.6% year-over-year.
- Ranks #72 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$22.3M | +73.6% |
| FY2024 | -$84.6M | +28.9% |
| FY2023 | -$119.0M | -3863.3% |
| FY2022 | $3.2M | +0.0% |
| FY2021 | $3.2M | +114.6% |
| FY2020 | -$21.6M | -461.2% |
| FY2019 | -$3.8M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026